VIVIMEDLAB
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Vivimed Labs Ltd Phaninder Nath Resigns As CFO
Feb 6 (Reuters) - Vivimed Labs Ltd VVMD.NS:
VIVIMED LABS LTD - CFO PHANINDER NATH P S RESIGNS FROM VIVIMED LABS
Source text: ID:nBSE2Vxs1b
Further company coverage: VVMD.NS
(([email protected];))
Feb 6 (Reuters) - Vivimed Labs Ltd VVMD.NS:
VIVIMED LABS LTD - CFO PHANINDER NATH P S RESIGNS FROM VIVIMED LABS
Source text: ID:nBSE2Vxs1b
Further company coverage: VVMD.NS
(([email protected];))
Vivimed Labs CFO And CS Receive Notice From CBI
Feb 3 (Reuters) - Vivimed Labs Ltd VVMD.NS:
VIVIMED LABS LTD - CFO AND CS RECEIVE NOTICE FROM CBI
VIVIMED LABS LTD - NOTICE AS STATE BANK OF INDIA FILES COMPLAINT ON FINANCIAL IRREGULARITIES
Source text: ID:nBSE1xyYmS
Further company coverage: VVMD.NS
(([email protected];))
Feb 3 (Reuters) - Vivimed Labs Ltd VVMD.NS:
VIVIMED LABS LTD - CFO AND CS RECEIVE NOTICE FROM CBI
VIVIMED LABS LTD - NOTICE AS STATE BANK OF INDIA FILES COMPLAINT ON FINANCIAL IRREGULARITIES
Source text: ID:nBSE1xyYmS
Further company coverage: VVMD.NS
(([email protected];))
Upcoming Events:
Quarterly Results
Events:
Dividend
Dividend
Split
Dividend
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Vivimed Labs do?
Vivimed Labs Limited, Established in 1991, has metamorphosed from a domestic small, entrepreneurial family-operated business to a globally renowned supplier of niche molecules and formulations across Healthcare, Pharmaceuticals and Specialty Chemicals consumers in several countries. The company's presence in Active Pharmaceutical Ingredients (API), Finished Dosage Formulation (FDF) and Retail Branded Formulation manufacturing, caters to the inner health of people. Within the FDF business, it provides contract manufacturing services and the manufacture of branded formulations. The active ingredients manufactured by the company are the preferred ingredients in Home & Personal care segments such as hair, skin, oral care and anti-microbial preservatives, by leading global FMCG conglomerates. The company's current product portfolio caters to over 75% of the ingredient market. The company is also present in the Industrial care segments such as, photo chromic dyes and imaging chemicals. The company will soon be expanding its operations into the fast-emerging and highly demanding sector of Printable Electronics and Organic Semiconductors.
Who are the competitors of Vivimed Labs?
Vivimed Labs major competitors are Biofil Chem & Pharma, Makers Laboratories, Murae Organisor, Bharat Immunological, Deccan Health Care, Dipna Pharma., JFL Life Sciences. Market Cap of Vivimed Labs is ₹63 Crs. While the median market cap of its peers are ₹53 Crs.
Is Vivimed Labs financially stable compared to its competitors?
Vivimed Labs seems to be less financially stable compared to its competitors. Altman Z score of Vivimed Labs is -0.16 and is ranked 8 out of its 8 competitors.
Does Vivimed Labs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vivimed Labs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Vivimed Labs allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Vivimed Labs balance sheet?
Vivimed Labs balance sheet is weak and might have solvency issues
Is the profitablity of Vivimed Labs improving?
Yes, profit is increasing. The profit of Vivimed Labs is -₹24.37 Crs for TTM, -₹31.96 Crs for Mar 2025 and -₹45.45 Crs for Mar 2024.
Is the debt of Vivimed Labs increasing or decreasing?
Yes, The net debt of Vivimed Labs is increasing. Latest net debt of Vivimed Labs is ₹383 Crs as of Sep-25. This is greater than Mar-25 when it was ₹375 Crs.
Is Vivimed Labs stock expensive?
Vivimed Labs is not expensive. Latest PE of Vivimed Labs is 0, while 3 year average PE is 0.74. Also latest EV/EBITDA of Vivimed Labs is 0.0 while 3yr average is 18.66.
Has the share price of Vivimed Labs grown faster than its competition?
Vivimed Labs has given lower returns compared to its competitors. Vivimed Labs has grown at ~-8.3% over the last 3yrs while peers have grown at a median rate of -5.92%
Is the promoter bullish about Vivimed Labs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Vivimed Labs is 7.77% and last quarter promoter holding is 7.77%.
Are mutual funds buying/selling Vivimed Labs?
There is Insufficient data to gauge this.
